Search research articles
Contact Us
Filters
Showing results (141-150 of 282) with videos related to
Page
of 29
Sort By:
The Journal of Clinical Investigation
|
September 17, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
Nima Sharifi, Robert Diaz, Hui-Ming Lin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
June 18, 2016
The role of mindfulness in distress and quality of life for men with advanced prostate cancer
Suzanne K Chambers, Elizabeth Foley, Samantha Clutton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial
Suzanne K Chambers, Stefano Occhipinti, Elizabeth Foley, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 4, 2006
Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1
Heather Jackson, Nektaria Dimopoulos, Nicole A Mifsud, et al.
Cancer Immunity
|
September 24, 2004
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
Mark Shackleton, Ian D Davis, Wendie Hopkins, et al.
Stem Cell Reviews and Reports
|
October 31, 2015
Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro
Craig Gedye, Tracy Cardwell, Nektaria Dimopoulos, et al.
BJU International
|
June 12, 2023
Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?
Matthew J Roberts, George Hruby, Andrew Kneebone, et al.
Kidney Cancer (Clifton, Va.)
|
February 12, 2019
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial
Nicola J Lawrence, Andrew Martin, Ian D Davis, et al.
Cancer Research
|
April 17, 2008
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells
Lisa M Ebert, Bee Shin Tan, Judy Browning, et al.
BJU International
|
October 23, 2019
TheraP: a randomized phase 2 trial of <sup>177</sup> Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Michael S Hofman, Louise Emmett, John Violet, et al.
Page
of 29
Search research articles
Search
Showing results (141-150 of 282) with videos related to
Sort By:
Page
of 29
The Journal of Clinical Investigation
|
September 17, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
Nima Sharifi, Robert Diaz, Hui-Ming Lin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
June 18, 2016
The role of mindfulness in distress and quality of life for men with advanced prostate cancer
Suzanne K Chambers, Elizabeth Foley, Samantha Clutton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial
Suzanne K Chambers, Stefano Occhipinti, Elizabeth Foley, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 4, 2006
Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1
Heather Jackson, Nektaria Dimopoulos, Nicole A Mifsud, et al.
Cancer Immunity
|
September 24, 2004
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
Mark Shackleton, Ian D Davis, Wendie Hopkins, et al.
Stem Cell Reviews and Reports
|
October 31, 2015
Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro
Craig Gedye, Tracy Cardwell, Nektaria Dimopoulos, et al.
BJU International
|
June 12, 2023
Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?
Matthew J Roberts, George Hruby, Andrew Kneebone, et al.
Kidney Cancer (Clifton, Va.)
|
February 12, 2019
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial
Nicola J Lawrence, Andrew Martin, Ian D Davis, et al.
Cancer Research
|
April 17, 2008
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells
Lisa M Ebert, Bee Shin Tan, Judy Browning, et al.
BJU International
|
October 23, 2019
TheraP: a randomized phase 2 trial of <sup>177</sup> Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Michael S Hofman, Louise Emmett, John Violet, et al.
Page
of 29